DBV Technologies | DBVT - Equity Capital And Reserves


DBV Technologies reported $168.77M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
DBV Technologies USD 168.77M 115.92M Dec/2025
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
Galectin Therapeutics USD -83.87M 11.06M Jun/2024
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Neurocrine Biosciences USD 3.41B 154.3M Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026